Changing Landscape of Diagnosis and Personalized Therapies for Acute Myeloid Leukemia

Friday, October 11, 2024, 8:00 AM - Friday, October 10, 2025, 11:59 PM

AMA PRA Category 1 Credits™ (1.50 hours), AMA PRA Category 1 Credits™ Designated (1.50 hours)


AML is the most common acute leukemia, with significant chromosomal translocations and mutations in the genes involved in hematopoietic proliferation and differentiation, resulting in the accumulation of poorly differentiated myeloid cells. AML is a highly heterogeneous disease with favorable, intermediate, and adverse-risk groups based on their cytogenetic profile. The prognosis within these categories varies widely. Identifying recurrent genetic mutations, such as FLT3-ITD, NMP1, and CEBPA, has helped refine individual prognosis and guide management. The selection of patients based on cytogenetic, molecular genetic markers, and human leukocyte antigen (HLA) testing and treatment with CPX-351, IDH1/2, FLT3, BCl-2, CD33, and Hedgehog pathway targeted agents, and HCT is the focus of the virtual live and enduring webcast.

There are no fees to participate in the activity. Participants must review all activity contents, including the learning objectives, disclosure statements, and post activity assessment to receive CME credit for participation.

Contact Information
Brian Waggoner, Program Manager
CancerNet, LLC
[email protected]

1. Assess pathophysiology, myelofibrosis symptom burden, and risk stratification in identifying myelofibrosis (MF) patients for optimal disease management;
2. Illustrate evidence-based risk-informed NCCN guideline-directed treatment strategies for MF.
3. Cite the treatment options with CPX-351, IDH1/2, FLT3, BCl-2, CD33, and Hedgehog pathway targeted agents in genomic subgroups of AML.

PHYSICIAN CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CancerNet. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSE PRACTIONERS CREDIT
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.5 hours.

PHYSICIAN ASSISTANT/ASSOCIATES CREDIT
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)^TM from organizations accredited by ACCME or a recognized state medical society.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Medical Director & Program Planners
The University of Cincinnati, CancerNet, and the peer/content reviewers for this activity have no relevant relationships to report.

CancerNet, LLC
Kamatham A. Naidu, PhD
Brian Waggoner

University of Cincinnati, Center for Continuous Professional Development
Susan P. Tyler, PhD, Associate Dean
Heather Muskopf, Program Director
Robert Ellis, MD, Peer Reviewer
Elizabeth Shaughnessy, MD Peer Reviewer
 
Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, and CancerNet. The information is presented for the purpose of advancing the attendees’ professional development.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Richard M. Stone, MD
Chief of Staff
Director, Translational Research, Adult Leukemia Program
Lunder Family Chair in Leukemia at Dana-Farber Institute
Physician, Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Stone discloses that he is an Advisory Board Member for: Abbvie, AvenCell, BMS, Amgen, Cellarity, CTI BioPharma, CTI Pharma, Daiichi Sankyo, GSK, Hermavant, Kura Onc, Lava Therapeutics, Ligand Pharma, Redona Therapeutics, and Rigel. Consultant for: ENSEM and Glycomimetrics. Data and Safety Monitoring Board Member for: Aptevo, Epizyme, Syntrix, and Takeda. Grand Rounds Participant for: Jazz. Steering Committee member for: Abbvie.  Speaker for: Curis Oncology

Harry P. Erba, MD, PhD
Professor of Medicine and Director of the Leukemia Program
Division of Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, NC

Dr. Erba discloses that he is a Consultant for: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb/Celgene, Daiichi Sankyo, Gilead, Glycomimetics, Incyte, Jazz, Kura Oncology, Novartis, Pfizer, Protagonist, Rigel, Schrodinger, Servier, Stemline, and Sumitomo Pharma. Received Research Support from: AbbVie, ALX Oncology, Amgen, Aptose, Ascentage, Daiichi Sankyo, Forma, Gilead, Glycomimetics, Immunogen, Jazz, Kura Oncology, MacroGenics, Novartis, Oryzon, PTC Therapeutics, Stemline, Sumitomo Pharma, and Taiho Oncology. Speaker for: AbbVie, Agios, Bristol Myers Squibb/Celgene, Incyte, Jazz, Servier, and Syndax.

 

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

 

This activity is supported by an educational grant from Daiichi Sankyo, Inc.